Trial · NCT07887867
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Achieving Eczema Area and Severity Index (EASI) <7 | Week 24 | |
| Secondary | EASI 90 | Week 4, 12, 24, 52 | Proportion of participants reaching 90% improvement in EASI from baseline |
| Secondary | Change from baseline in Eczema Area and Severity Index (EASI) Score | Baseline, Week 4, 12, 24, 52 | |
| Secondary | Change from baseline in Peak Pruritus-Numeric Rating Scale (PP-NRS) Score | Baseline, Week 4, 12, 24, 52 | |
| Secondary | Percentage of Participants Achieving PP-NRS <=1 | Week 4, 12, 24, 52 | |
| Secondary | Change from baseline in Investigator's Global Assessment (IGA) Score | Week 4, 12, 24, 52 | |
| Secondary | Percentage of Participants Achieving IGA 0-1 | Week 4, 12, 24, 52 | |
| Secondary | Change from baseline in Dermatology Life Quality Index (DLQI) Score | Week 4, 12, 24, 52 | |
| Secondary | Change From Baseline in Patient-Oriented Eczema Measure (POEM) Score | Week 4, 12, 24, 52 | |
| Secondary | Change from baseline in Sleep Disturbance Numeric Rating Scale (SD-NRS) Score | Week 4, 12, 24, 52 | |
| Secondary | Percentage of Participants Achieving Minimal Disease Activity (MDA) | Week 4, 12, 24, 52 | |
| Secondary | Demographics Characteristics: Percentage of Participants by Age, Gender, Education, Occupation, Family Status | Baseline | |
| Secondary | Number of Participants by Age-at-Onset Category for Atopic Dermatitis | Baseline | Age at onset |
| Secondary | Number of Participants by Atopic Dermatitis Phenotype | Baselines, Week 4, 12, 24, 52 | |
| Secondary | Number of Participants with Each Difficult-to-Treat Body Area | Baseline, Week 4, 12, 24, 52 | |
| Secondary | Clinical Characteristics: Duration of Previous Advanced Therapy Before Switching to Abrocitinib | Baseline | |
| Secondary | Number of participants with Each Atopic Comorbidity | Baseline, Week 4,12,24,52 | |
| Secondary | Number of Participants with Each Non-Atopic Comorbidity | Baseline, Week 4,12,24,52 | |
| Secondary | Adherence to Abrocitinib | Week 4,12, 24, 52 | Percentage of actual vs. expected therapeutic dosages as reported by the participants. |
| Secondary | Persistence to Abrocitinib | Week 52 | Percentage of participants on treatment at week 52. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07887867/registered